Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Michael Miller, M.D.,Ph.D.

Other Positions

Food and Drug Administration, Silver Spring, Maryland10/2018Regulatory Medicine
University of Massachusetts Medical School, Worcester, MAMD/PhD05/2010Medicine/Biomedical Science
Brigham and Women's Hospital, Boston, MA6/2015Internal Medicine
Columbia University Medical Center, New York, New York6/2014Dermatology
Beth Israel Deaconess Medical Center, Boston, MA12/2018Hematology/Oncology

Available: 03/28/19, Expires: 03/26/20

We are developing a patient registry of patients with non-melanoma skin cancer at MGH. Student would be involved with development of a database for patients with keratinocyte carcinoma and for data capture and data quality of the currently existing Merkel Cell Carcinoma patient registry. The project will involve participating in our multidiscplinary NMSC program and allow for the development of data science skills.

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. Paul Carbone, MD Fellowship Award (David Miller) Jul 1, 2018 - Jun 30, 2019
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Miller DM, Trowbridge RM, Desai A, Drews RE. Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab. J Immunother Cancer. 2018 Nov 19; 6(1):122. PMID: 30454071.
    Citations:    Fields:    
  2. Klebanov N, Gunasekera NS, Lin WM, Hawryluk EB, Miller DM, Reddy BY, Christman MP, Beaulieu D, Rajadurai S, Duncan LM, Sober AJ, Tsao H. Clinical spectrum of cutaneous melanoma morphology. J Am Acad Dermatol. 2019 Jan; 80(1):178-188.e3. PMID: 30165162.
    Citations:    Fields:    
  3. Eliades P, Abraham BJ, Ji Z, Miller DM, Christensen CL, Kwiatkowski N, Kumar R, Njauw CN, Taylor M, Miao B, Zhang T, Wong KK, Gray NS, Young RA, Tsao H. High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. J Invest Dermatol. 2018 07; 138(7):1582-1590. PMID: 29408204.
    Citations: 1     Fields:    
  4. Miller DM, Faulkner-Jones BE, Stone JR, Drews RE. Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. JAAD Case Rep. 2017 Sep; 3(5):412-415. PMID: 28932782.
    Citations: 3     
  5. Reddy BY, Miller DM, Tsao H. Somatic driver mutations in melanoma. Cancer. 2017 06 01; 123(S11):2104-2117. PMID: 28543693.
    Citations: 3     Fields:    Translation:Humans
  6. Eliades P, Miller DM, Miao B, Kumar R, Taylor M, Buch S, Srinivasa SP, Flaherty KT, Tsao H. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biol Ther. 2016 07 02; 17(7):778-84. PMID: 26810603.
    Citations:    Fields:    Translation:HumansCells
  7. Miller DM, Flaherty KT, Tsao H. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Semin Cutan Med Surg. 2014 Jun; 33(2):60-7. PMID: 25085663.
    Citations: 5     Fields:    Translation:Humans
  8. Miller DM, Flaherty KT, Tsao H. Commentary: Molecular testing in melanoma. J Am Acad Dermatol. 2014 May; 70(5):863-70. PMID: 24534656.
    Citations: 1     Fields:    Translation:Humans
  9. Miller DM, Flaherty KT. Cyclin-dependent kinases as therapeutic targets in melanoma. Pigment Cell Melanoma Res. 2014 May; 27(3):351-65. PMID: 24405945.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  10. Brehm MA, Cuthbert A, Yang C, Miller DM, DiIorio P, Laning J, Burzenski L, Gott B, Foreman O, Kavirayani A, Herlihy M, Rossini AA, Shultz LD, Greiner DL. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol. 2010 Apr; 135(1):84-98. PMID: 20096637.
    Citations: 85     Fields:    Translation:HumansAnimalsCells
  11. Miller DM, Thornley TB, Pearson T, Kruger AJ, Yamazaki M, Shultz LD, Welsh RM, Brehm MA, Rossini AA, Greiner DL. TLR agonists prevent the establishment of allogeneic hematopoietic chimerism in mice treated with costimulation blockade. J Immunol. 2009 May 01; 182(9):5547-59. PMID: 19380803.
    Citations: 6     Fields:    Translation:AnimalsCells
  12. Miller DM, Thornley T, Pearson T, Yamazaki M, Brehm MA, Rossini AA, Greiner DL. TLR agonists abrogate co-stimulation blockade-induced mixed chimerism and transplantation tolerance. Ann N Y Acad Sci. 2008 Dec; 1150:149-51. PMID: 19120285.
    Citations: 2     Fields:    Translation:AnimalsCells
  13. Pearson T, Shultz LD, Miller D, King M, Laning J, Fodor W, Cuthbert A, Burzenski L, Gott B, Lyons B, Foreman O, Rossini AA, Greiner DL. Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol. 2008 Nov; 154(2):270-84. PMID: 18785974.
    Citations: 53     Fields:    Translation:HumansAnimals
  14. Miller DM, Thornley TB, Greiner DL, Rossini AA. Viral infection: a potent barrier to transplantation tolerance. Clin Dev Immunol. 2008; 2008:742810. PMID: 18815618.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  15. Miller DM, Rossini AA, Greiner DL. Role of innate immunity in transplantation tolerance. Crit Rev Immunol. 2008; 28(5):403-39. PMID: 19166387.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  16. Yamazaki M, Pearson T, Brehm MA, Miller DM, Mangada JA, Markees TG, Shultz LD, Mordes JP, Rossini AA, Greiner DL. Different mechanisms control peripheral and central tolerance in hematopoietic chimeric mice. Am J Transplant. 2007 Jul; 7(7):1710-21. PMID: 17564635.
    Citations: 9     Fields:    Translation:AnimalsCells
  17. Cole EB, Miller D, Rometo D, Greenberg RM, Brömme D, Cataltepe S, Pak SC, Mills DR, Silverman GA, Luke CJ. Identification and activity of a lower eukaryotic serine proteinase inhibitor (serpin) from Cyanea capillata: analysis of a jellyfish serpin, jellypin. Biochemistry. 2004 Sep 21; 43(37):11750-9. PMID: 15362859.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  18. Al-Khunaizi M, Luke CJ, Askew YS, Pak SC, Askew DJ, Cataltepe S, Miller D, Mills DR, Tsu C, Brömme D, Irving JA, Whisstock JC, Silverman GA. The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases. Biochemistry. 2002 Mar 05; 41(9):3189-99. PMID: 11863458.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Miller's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (127)
Co-Authors (17)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.